Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Arctic Bioscience AS ( (DE:9TD) ) just unveiled an announcement.
Arctic Bioscience announced the release of their Q4 2024 operational update, scheduled for February 27, 2025. The company will host a webcast to present the results and provide an operational update, including a Q&A session. This announcement is part of the company’s ongoing efforts to keep stakeholders informed and engaged, reflecting its commitment to transparency and communication. The update could provide insights into the company’s strategic direction and performance, impacting its positioning in the biotech industry.
More about Arctic Bioscience AS
Arctic Bioscience is a biotech company specializing in the development and commercialization of pharmaceutical and nutraceutical products derived from unique bioactive marine compounds. The company is currently advancing HRO350, an oral drug candidate for mild-to-moderate psoriasis, a condition affecting a large patient group in need of effective treatments with a favorable safety profile. Their nutraceutical products are marketed globally under the ROMEGA® brand.
YTD Price Performance: 58.46%
Average Trading Volume: 1,500
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €6.62M
See more data about 9TD stock on TipRanks’ Stock Analysis page.
